According to the announcement of Tianjin Pharmaceutical, the company's subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” for compound amino acid injections approved and issued by the State Drug Administration. The drug is a four-class chemical injection, with a specification of 200ml: 20.650 g. After approval, it is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs, and is used for hypoproteinemia, low nutritional status, and amino acid supplementation before and after surgery. The approval of the drug will improve the company's formulation product range, which will have a positive impact on expanding the domestic formulation market and improving performance.

According to the announcement of Tianjin Pharmaceutical, the company's subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” for compound amino acid injections approved and issued by the State Drug Administration. The drug is a four-class chemical injection, with a specification of 200ml: 20.650 g. After approval, it is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs, and is used for hypoproteinemia, low nutritional status, and amino acid supplementation before and after surgery. The approval of the drug will improve the company's formulation product range, which will have a positive impact on expanding the domestic formulation market and improving performance.